Increased Sphingosine Kinase 1 Expression Predicts Distant Metastasis and Poor Outcome in Patients With Colorectal Cancer

Bae, Go Eun; Im, Sung Il; Kim, Kyungeun; Park, Ji Hyun; Cho, SiHyun; Kim, Hyunsoo

doi:10.21873/anticanres.13161

Cited by 26 publications

(25 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are many examples of SK1 upregulation at the mRNA and protein level, which is often associated with poor prognosis including reduced survival and earlier disease recurrence in cancer patients [2]. Recent examples include melanoma [62], papillary thyroid carcinoma [84], non-small cell lung cancer [85], triple-negative breast cancer [86] and colorectal cancer [87]. This is consistent with the ability of SK1 to promote cell survival, proliferation and neoplastic transformation and supports the therapeutic potential of SK1 inhibitors.…”

Section: Sk1/sk2 and Cancermentioning

confidence: 57%

Recent advances in the role of sphingosine 1‐phosphate in cancer

Pyne

2020

FEBS Letters

View full text Add to dashboard Cite

Sphingosine 1-phosphate (S1P) is a bioactive lipid that binds to a family of G protein-coupled receptors (S1P 1-5) and intracellular targets, such as HDAC1/ 2, that are functional in normal and pathophysiologic cell biology. There is a significant role for sphingosine 1-phosphate in cancer underpinning the socalled hallmarks, such as transformation and replicative immortality. In this review, we survey the most recent developments concerning the role of sphingosine 1-phosphate receptors, sphingosine kinase and S1P lyase in cancer and the prognostic indications of these receptors and enzymes in terms of diseasespecific survival and recurrence. We also provide evidence for identification of new therapeutic approaches targeting sphingosine 1-phosphate to prevent neovascularisation, to revert aggressive and drug-resistant cancers to more amenable forms sensitive to chemotherapy, and to induce cytotoxicity in cancer cells. Finally, we briefly describe current advances in the development of isoform-specific inhibitors of sphingosine kinases for potential use in the treatment of various cancers, where these enzymes have a predominant role. This review will therefore highlight sphingosine 1-phosphate signalling as a promising translational target for precision medicine in stratified cancer patients.

show abstract

Section: Sk1/sk2 and Cancermentioning

confidence: 57%

Recent advances in the role of sphingosine 1‐phosphate in cancer

Pyne

2020

FEBS Letters

View full text Add to dashboard Cite

show abstract

“…High SPHK1 expression in CRC cell lines and tissue samples has been reported. Also, the key role of SPHK1 in tumor development and progression and its significant association with invasion and metastasis were confirmed [16]. So its role in CSC niche might be important.…”

mentioning

confidence: 85%

Targeting the SPHK1/HIF1 Pathway to Inhibit Colorectal Cancer Stem Cells Niche

Khoei

Sadeghi

Dermani

2019

J Gastrointest Canc

View full text Add to dashboard Cite

“…Immunohistochemical staining. Immunostaining was performed using an automatic instrument [Ventana Benchmark XT (Ventana Medical Systems, Oro Valley, AZ, USA)] (10)(11)(12)(13)(14)(15)(16)(17)(18). Antigen retrieval was performed using the Cell Conditioning Solution (CC1, Ventana Medical Systems).…”

Section: Methodsmentioning

confidence: 99%

Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix

Jung

Bae

Kim

et al. 2020

Cancer Genomics Proteomics

Self Cite

View full text Add to dashboard Cite

Background/Aim: We investigated differences in the clinicopathological and molecular characteristics between gastric-type mucinous carcinoma (GMC) and usualtype endocervical adenocarcinoma (UEA). Patients and Methods: We collected the clinicopathological information and performed targeted genomic sequencing analysis. Results: GMCs exhibited significantly deeper invasion depth, larger horizontal spread, more advanced stage, more frequent distant metastasis, and more frequent parametrial and vaginal extension. Disease-free survival time of GMC patients was significantly shorter than that of UEA patients. GMCs displayed mutant p53 immunostaining pattern, whereas UEAs exhibited p16 block positivity. GMCs harbored mutations in KRAS, TP53, NF1, CDKN2A, STK11, and ARID1A. One GMC exhibited MDM2 amplification. In contrast, UEAs harbored mutations in HRAS, PIK3CA, and BRCA2. Two UEAs were found to have novel TP53 mutations. Conclusion: GMC is associated with more aggressive behavior than UEA. Distinctive p53 and p16 immunostaining patterns enable differential diagnosis. GMC and UEA exhibit genetic heterogeneity with potentially actionable molecular alterations. Cervical cancer is the fourth most common gynecological malignancy and the fourth leading cause of cancer-related death in women worldwide (1, 2), although cervicovaginal cytology screening decreased the incidence rate of cervical cancer and its associated mortality rate. Adenocarcinoma of the uterine cervix is relatively less common than squamous cell carcinoma and accounts for approximately 10-20% of all cervical cancers (3, 4). However, despite the declined incidence of cervical cancer, the proportion of endocervical adenocarcinoma has increased (4-6). The International Endocervical Adenocarcinoma Criteria and Classification (IECC) is a recent system to classify endocervical adenocarcinoma into human papillomavirus (HPV)-associated adenocarcinoma (HPVA) and non-HPV-associated adenocarcinoma (NHPVA) categories based on morphological features (7). Identification of high-risk HPV, notable mitotic activity, and numerous apoptotic bodies across the glandular lumina allowed diagnosing HPVAs. The HPVAs were further divided into usual type, mucinous type (intestinal type, signet ring cell type, and not otherwise specified), villoglandular type, and invasive stratified mucin-producing carcinoma (invasive stratified mucin-producing intraepithelial lesion), depending on their cytoplasmic mucin component and nuclear characteristics. Meanwhile, NHPVAs include gastric-type mucinous carcinoma (GMC), mesonephric carcinoma, serous carcinoma, clear cell carcinoma, and endometrioid adenocarcinoma. Among these carcinomas, GMC, which is the second most common subtype of endocervical adenocarcinoma, is included in the 2014 World Health Organization (WHO) Classification of Tumours of Female Reproductive Organs (1). Although the incidence of 627 This article is freely accessible online.

show abstract

Increased Sphingosine Kinase 1 Expression Predicts Distant Metastasis and Poor Outcome in Patients With Colorectal Cancer

Cited by 26 publications

References 32 publications

Recent advances in the role of sphingosine 1‐phosphate in cancer

Recent advances in the role of sphingosine 1‐phosphate in cancer

Targeting the SPHK1/HIF1 Pathway to Inhibit Colorectal Cancer Stem Cells Niche

Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix

Contact Info

Product

Resources

About